Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

23
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
23
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

20
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
20
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

19
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
19
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

24
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
24
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.2K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.2K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

392
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
392

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors Associated with the Impact of Regulatory Safety Advisories on Medicine Use: A Meta-regression Analysis.

Journal of general internal medicine·2026
Same author

Estimating prevalence and predictors of glucose-lowering overtreatment among older adults with type 2 diabetes in long-term care and community settings: a machine learning-based cohort study.

BMJ open·2026
Same author

The impact of eliminating out-of-pocket payments for medicines on low-income households: a controlled interrupted time series analysis using linked administrative data from British Columbia.

Health policy (Amsterdam, Netherlands)·2025
Same author

Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States.

Clinical epidemiology·2024
Same author

Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications.

JAMA network open·2023
Same author

Validity of diagnoses of SARS-CoV-2 infection in Canadian administrative health data: a multiprovince, population-based cohort study.

CMAJ open·2023

Related Experiment Video

Updated: Feb 20, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K

Using policy simulation to predict drug plan expenditure when planning reimbursement changes.

Colin R Dormuth1, Sean Burnett, Sebastian Schneeweiss

  • 1Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts 02120, USA. cdormuth@hsph.harvard.edu

Pharmacoeconomics
|October 21, 2005
PubMed
Summary

A new drug policy simulator accurately projected financial impacts with less than 1% error, aiding decision-makers. This tool enhances drug policy planning by providing rapid, clear financial forecasts for health plans.

More Related Videos

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System
08:25

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

16.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

Related Experiment Videos

Last Updated: Feb 20, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K
Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System
08:25

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

16.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

Area of Science:

  • Health Economics
  • Health Policy Analysis
  • Pharmacoeconomics

Background:

  • Accurate financial impact projections are crucial for drug plan decision-makers implementing new policies.
  • Existing ad hoc methods for financial impact projections by health plans are often inadequate.
  • Tools for financial impact projections require small margins of error and clear communication of methodology.

Purpose of the Study:

  • To introduce a flexible tool for projecting the financial impact of drug policy changes.
  • To validate the tool using historical dispensing data and simulation.
  • To explore the tool's validity with a complex drug policy change in British Columbia, Canada.

Main Methods:

  • A policy simulator program with a Web browser interface was utilized.
  • The simulator produced 3-year expenditure forecasts based on historical prescription claim records (British Columbia PharmaNet database).
  • Prediction accuracy was tested by comparing simulated expenditure with actual PharmaCare expenditure post-policy implementation.

Main Results:

  • The policy simulation tool generated numerous policy variations for decision-makers.
  • The tool predicted drug spending with less than 1% error for 11 months post-policy introduction.
  • The simulator accurately forecasted both insurer expenditure and family out-of-pocket costs.

Conclusions:

  • The simulator facilitated drug policy planning and communication.
  • The tool delivered rapid, accurate results that were easily communicated to stakeholders.
  • This policy simulation approach is applicable to diverse health plans and policy changes.